Qiagen GmbH, which earlier this month went public on NASDAQ, provided proof of principle that a German company could present itself credibly to do a mainstream public offering in the U.S., and that American investors would invest in German-based biotech companies.

This should give some comfort to the emerging biotech sector in Germany, where access to capital has been a struggle